SpicyIP Tidbit: Free Trade Agreement- No smooth sailing here.


The chances of the Free Trade Agreement between India and the EU materializing seem bleak now with differences between the parties continuing after another round of negotiations. As The Hindu reports, “Although both sides have stated that good progress had been made in the first three rounds, officials in the 27-member block European Union feel that signing of the FTA by this year-end was near impossible.” While the parties have postponed the next round of negotiations, officials do not seem…


Read More »

Spicy Tidbit: 2nd day at the Annual Global Forum on Innovation, Creativity and Intellectual Property


Today was the 2nd day of the 2nd Annual Global Forum on Innovation, Creativity and Intellectual Property organised by CII in conjunction with the Department of Industrial Policy and Promotion, GOI and the US India Business Council (Mumbai). The day began with a discussion on “Global trends in IP Protection” where Narendra K. Sabharwal, Deputy Director General, World Intellectual Property Organisation spoke of the following – shift in focus of IP community from protection of IP to promotion and exploitation…


Read More »

Chinese pharma poses serious competition to Indian Pharma: PharmaBiz


PharmaBiz.com reports that Chinese pharmaceutical companies are posing a serious threat to their Indian counterparts. As usual the Chinese who are past-masters at reverse engineering have started manufacturing drugs at prices cheaper than Indian drugs. Active pharmaceutical ingredient (API) units in India have already faced severe competition in the country during the last ten years leading to several units shutting down but the threat now is to the formulations industry. The Indian pharmaceutical industry is lobbying hard to ensure that…


Read More »

SpicyIP Tidbits: IPR Index


According to an article in the Intellectual Assets Magazine (IAM), Property Rights Alliance (PRA) released its International Property Rights Index (IPRI) Report for the year 2008, with rankings on protection for physical and intellectual property in 115 countries. In IP protection, among emerging economies, India ranks 47th along with Mauritania, with Brazil, China and Russia on 49th, 70th and 82nd positions respectively. Finland topped the rankings with Germany, UK and Japan occupying the next three slots; the US is ranked…


Read More »
Trademark

SpicyIP Tidbits: Times Group loses domain name dispute


In a super-quick typosquatting dispute decision, the Times of Money, the online remittance subsidiary of Indian media conglomerate Times Group, has been directed to transfer its two domain names, remit2home.com and remit2home1.com, to remithome Corporation, a U.S. to Philippines online remittance service based in Oakland, California (www.remithome.com), according to this report. The decision came from the US National Arbitration Forum, designated to deal with domain name disputes by the Internet Corporation for Assigned Names and Numbers (ICANN). It ruled on…


Read More »
Copyright

SpicyIP Tidbits: YouTube & T-series heading for out-of-court settlement?


This is what Nikhil Pahwa’s post at contentsutra.com seems to suggest, with the Delhi High Court having given the two parties time to settle their copyright infringement dispute. The next hearing is slated for July, but the general mood at the hearing in late-February gave the impression that the two would prefer dealing outside the confines of the Indian judicial system. Notwithstanding the irony of T-Series suing for copyright infringement, if the settlement were to go through, it would deny…


Read More »

SpicyIP Tidbits: Lipitor Case


Last week, we had reported that Ranbaxy was prohibited by the Court of Appeal in Netherlands from launching a generic version of Pfizer’s basic Lipitor patent on atorvastatin (EP 247633). In an interesting reversal of fortunes, the same court has invalidated Pfizer’s patent on the enantiomer of atorvastatin (EP 409281) which was challenged by Ranbaxy. Pfizer may prefer an appeal against this ruling. It may be recalled that the Nexium case too deals with patent on S-enantiomer of Omeprazole, namely…


Read More »
Patent

Natco vs Pfizer: Today’s Hearing at the Patent Office


The Assistant Controller (Delhi Patent Office), Mr Dev Karar heard counsels appearing for Natco and Pfizer today. The hearing was limited to the interlocutory petition filed by Natco challenging the legality of the “hearing” granted to Pfizer. The Asst Controller stated that he would issue a decision on this in about 10 days or so. For our previous posts on this case, see here, here, here and here. Interestingly, I had interviewed Dev Karar some years back for a paper…


Read More »
Patent

Natco vs Roche (Doha License): First Day


I’ve been given to understand that Natco’s counsel presented arguments before the patent office today. However, it appears that most of the arguments were centered around the interlocutory application filed by Natco, opposing the move by the patent office to hear Roche/Pfizer. Tomorrow, the patent office will hear arguments in this regard from counsels representing Pfizer/Roche. It is only after they decide on this interlocutory application (i.e. that parties cannot be heard under section 92A) that the matter will be…


Read More »
Patent

SpicyIP Tidbit: Sun challengesJ&J


Sun Pharma has as of February 28th, 2008 decided to file a post grant opposition with the Mumbai patent office against a product patent extension granted to Johnson & Johnson’s Risperdal, used to treat psychological disorders and schizophrenia. The patent, granted to Janssen Pharmaceutica, a group company of Johnson & Johnson, on July 20, 2007, with patent number 208191 relates to sustained-release particles of risperidone.Sun Pharma has been marketing a generic version of this drug for the last few years…


Read More »